- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03859817
Observational Study to Evaluate the Relationship Between Ketonemia and Renal Function in the Diabetic Patient (TAKEN-DKD)
A multicentre real life study is proposed. The study has as its goal primary to compare the levels of ketonemia measured in patients with albuminuria and patients normo albuminurici to evaluate a possible correlation between ketone level and alteration of renal function in the diabetic patient, comparing the eGFR values of patients with ketonemia high and of patients with low ketonemia. In these patients, the lack of insulin causes one imbalance between ketogenesis and ketolysis, with increased production and reduced body clearance ketones. Several studies explore the effects of ketone bodies on cell function and lesions diabetic complications: ketonemia induces oxidative stress and increases the risk and the progression of complications, moreover, the increase in ketone levels may have pro-inflammatory effects. However, ketonemia levels between normal and DKA are poorly studied and their effects are still unknown. It is hypothesized that
- in diabetic patients with DKD the level of ketones may be high;
- Increased ketone levels may promote an alteration of renal function.
We want to evaluate the relationship between ketone levels and renal function, because the kidneys, as well as the heart, are among the main organs in which the ketone bodies are oxidized to produce energy and DKD has a high morbidity and mortality in diabetes. The main objectives for being able to demonstrate the hypothesis in question are:
- Evaluate the level of ketones in albuminurate patients with diabetes and in patients with renal function altered;
- Evaluate the association between ketone level and decline of renal function in the diabetic patient e therefore the impact of ketonemia on the progression of renal function loss.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At the beginning and during the course of the study the glycemic and ketone index obtained by the homologous blood glucose monitoring will be evaluated. During the study, prognostic biomarkers (sP2X7R, KIM-1, sTNFR1, 11-dehydro-tromoxane B2 and 6-keto-prostaglandin-F-1a (PGF1α)), which are presumed to play an important role in inflammatory renal diseases, will also be measured in diabetic subject, in addition to the traditional marker that is the urinary albumin.
Step 1. Visit Baseline: blood sampling and collection of a urinary sample, evaluation proteinuria, GFR and blood and urinary ketones Step 2. Visit at 6 months: blood collection and collection of a urinary sample, evaluation proteinuria, GFR and blood and urinary ketones Step 3. Visit at 12 months: blood collection and collection of a urinary sample, evaluation proteinuria, GFR and blood and urinary ketones. The study involves the enrollment of T1D and T2D subjects in diabetic nephropathy. The study involves the enrollment of T1D and T2D subjects in diabetic nephropathy A timetable will be prepared for the surgeries during the which the diabetic subject will be informed about the study protocol in question and will provide eventual informed consent to entry into the study, blood sampling and urinary sample collection. However, the analysis will be above all exploratory and will allow to foresee possible studies future properly sized.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Milano, Italy, 20157
- ASST FBF-Sacco P.O. Sacco/Fatebenefratelli e Oftalmico
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Presence of albuminuria (≥30 mg / 24h)
- Adult and male patients of age
- Diagnosis of type 1 or type 2 diabetes according to the ADA diagnostic criteria
- Presence of the disease for at least five years
- HbA1c≥7%
- Written informed consent of the patient and / or parents or legal guardian
Exclusion Criteria:
Chronic end-stage renal disease (CKD5)
- Current or previous treatments with immunosuppressants (with the exception of topical steroids ed inhalers)
- Participation in other clinical studies
- Significant disease other than diabetes found in the two weeks prior to the first visit
- Neurological or psychiatric diseases, hemoglobinopathies, liver diseases, cancer, cystic fibrosis, renal failure, malabsorption syndromes
- Abuse of alcohol and drugs
- HIV or hepatitis
- Pregnant or lactating women (β-HCG urinary should be evaluated before each visit)
- Presence of serious diseases or conditions of the patient considered unsuitable by the Investigator for be able to include it in the study
- Poor understanding by the patient of spoken and written Italian
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with albuminuria
Comparison of eGFR values and ketonemia in diabetic patients
|
To verify if there is a correlation between the level of ketones and an alteration of the renal function in the diabetic patient, the values of the prognostic markers indicated in the protocol and the data downloaded by the glucometers will be evaluated in addition to the blood tests of the patients
|
patients with normo albuminuria
Comparison of eGFR values and ketonemia in diabetic patients
|
To verify if there is a correlation between the level of ketones and an alteration of the renal function in the diabetic patient, the values of the prognostic markers indicated in the protocol and the data downloaded by the glucometers will be evaluated in addition to the blood tests of the patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Variations in albuminuria and albumin / creatinine ratio in urine (UACR)
Time Frame: 12 months
|
immunoturbidimetric method
|
12 months
|
Variations of the eGFR (CKD-EPI formula)
Time Frame: 12 months
|
CKD-EPI formula
|
12 months
|
Variations in ketone levels
Time Frame: 12 months
|
monitoring ketones in capillary and urinary samples
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Variations of tubular function markers (sP2X7R, KIM-1, sTNFR1)
Time Frame: 12 months
|
enzyme immunoassay (ELISA)
|
12 months
|
Variations of markers of glomerular function (11-dehydro-tromoxane B2 and 6-keto-prostaglandin- F-1a (PGF1α))
Time Frame: 12 months
|
enzyme immunoassay (ELISA)
|
12 months
|
Changes in glycated hemoglobin (HbA1c)
Time Frame: 12 months
|
capillary electrophoresis
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018/ST/043
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Nephropathy Type 2
-
Beni-Suef UniversityUnknownDiabetic Nephropathy Type 2 | Microalbuminuria Due to Type 2 Diabetes MellitusEgypt
-
Akebia TherapeuticsCyclerion TherapeuticsCompletedType 2 Diabetes Mellitus With Diabetic NephropathyUnited States
-
Zheng GuoNot yet recruitingDiabetic Nephropathy Type 2
-
The Third Xiangya Hospital of Central South UniversityCompletedType 2 Diabetic NephropathyChina
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownDiabetic Nephropathy Type 2Mexico
-
Assiut UniversityUnknownDiabetic Nephropathy Type 2
-
Leiden University Medical CenterRadboud University Medical Center; Health Holland; Dutch Kidney FoundationCompletedGlucose Metabolism Disorders | Kidney Diseases | Diabetes Mellitus | Diabetic Nephropathies | Albuminuria | Microalbuminuria | Type2 Diabetes Mellitus | Diabetic Nephropathy Type 2 | Diabetic Complications Renal | South AsianNetherlands
-
Chinese PLA General HospitalBeijing Friendship Hospital; Xuanwu Hospital, Beijing; Beijing Tongren Hospital; Beijing Municipal Science & Technology Commission and other collaboratorsRecruitingDiabetic Kidney Disease | Type 2 Diabetes | Diabetic Nephropathy Type 2China
-
Second Affiliated Hospital, School of Medicine,...Second Affiliated Hospital of Wenzhou Medical University; Lishui Country People...RecruitingDiabetic Nephropathy Type 2 | BiomarkerChina
-
Assiut UniversityNot yet recruitingType 2 DM é Diabetic Nephropathy
Clinical Trials on Comparison of eGFR values and ketonemia in diabetic patients
-
Gaziosmanpasa Research and Education HospitalRecruiting
-
Cairo UniversityUnknown
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownHealthcare; Risk Prediction; Diabetic Patients With Osteoporosis
-
National University Hospital, SingaporeUnknown
-
Philipps University Marburg Medical CenterCompleted
-
Istituto Ortopedico GaleazziRecruitingTo Evaluate a Linear Positive Correlation Between Plasma HbA1c and Synovial IL-6 in Diabetic PatientsItaly
-
Universitair Ziekenhuis BrusselRecruitingNutrition Disorders | Diabetic Foot UlcerBelgium
-
Gaziosmanpasa Research and Education HospitalRecruiting
-
Cukurova UniversityCompletedDiabetic Peripheral Neuropathy
-
University Hospital, MontpellierTerminatedMuscle Atrophy | Chronic Obstructive Pulmonary Disease (COPD) | Exacerbation CopdFrance